Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum
Pharvaris (PHVS) presented at the Cantor Fitzgerald conference, highlighting 87% reduction in HAE attacks with deucrictibant in Phase III trials. The company plans an on-demand launch in April 2025 and a prophylaxis filing in the first half of 2025. Management addressed safety concerns and outlined a broad commercial strategy. Shares are up 62% over the past year, with analysts setting price targets between $42 and $79.
How this was made
The 30-second read
Why it matters
The data represent a material clinical milestone that could shift valuation and trigger regulatory interactions.
Market read
First disclosure of pivotal Phase III results likely to move PHVS stock and influence the oral HAE market.
What to watch
Potential competition from other oral agents and the need for extensive commercial rollout may strain cash flow.
Background
Pharvaris presented at the Cantor Fitzgerald Global Healthcare Conference, outlining its Phase III results and launch plans.
Ticker impact
Pharvaris disclosed Phase III CHAPTER-3 trial results showing 87% reduction in HAE attack rates and announced a prophylaxis filing planned for early 2025.
upward pressure, potential 15-25% rally over the next weeks
Efficacy comparable to injectables and a clear regulatory filing timeline reduce uncertainty, while safety concerns remain limited.
Market effects
Strengthens the oral HAE therapeutic segment and may pressure competitors like Takeda's TAKHZYRO.
U.S. biotech investors likely to reprice PHVS; limited immediate effect on broader markets.
Highlights progress in bradykinin-mediated angioedema treatments, relevant to global specialty pharma.
Counterpoint
Safety signals (grade 3 liver enzyme elevations) could delay approval or limit market uptake.
Key entities
- CompanyPharvaris
Biotech developing oral B2 receptor antagonist deucrictibant for hereditary angioedema.
- ExecutiveWim Souverijns
Chief Commercial Officer discussing commercial strategy.
